Involvement of Guanylate Cyclase and K+ Channels in Relaxation Evoked by Ferulate Nitrate in Rat Aorta Artery

Total Page:16

File Type:pdf, Size:1020Kb

Involvement of Guanylate Cyclase and K+ Channels in Relaxation Evoked by Ferulate Nitrate in Rat Aorta Artery J Pharmacol Sci 118, 521 – 530 (2012) Journal of Pharmacological Sciences © The Japanese Pharmacological Society Full Paper Involvement of Guanylate Cyclase and K+ Channels in Relaxation Evoked by Ferulate Nitrate in Rat Aorta Artery Zhan-Qing Wang1,*, Jing-Feng Xu1, Jin-Ping Wang1, Wei-Juan Zhao1, and Ming Zeng1 1Department of Pharmacology, General Hospital of Beijing Military Command, Beijing 100700, China Received September 29, 2011; Accepted February 21, 2012 Abstract. Vasorelaxant properties of N-2-(ferulamidoethyl)-nitrate (ferulate nitrate, FLNT), a newly synthesized nitrate, were compared with those of isosorbide dinitrate, nicorandil, nitro- glycerin, and 8-bromoguanosine 3,5-cyclic monophosphate (8-Br-cGMP) in rat aorta pre-contracted by phenylephrine. FLNT produced vasorelaxation in a concentration-dependent manner (0.1 – 100 μM). The degree of relaxation induced by FLNT was similar to that induced by isosorbide dinitrate. In addition, removal of endothelium did not affect the relaxant effect of FLNT. FLNT caused a rightward shift of the cumulative concentration–response curves of phenylephrine and reduced the maximal efficacy of contraction. 1H-[1,2,4]Oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ, 10 μM) + and K -channel blockers charybdotoxin (CHT, 0.1 μM) and BaCl2 (1 μM) reduced the relaxant effect of FLNT in the endothelium-denuded arteries, whereas glibenclamide (1 μM) and 4-amino- pyridine (1 mM) failed to influence FLNT-induced vasorelaxation. Furthermore, in the presence of ODQ, both CHT (0.1 μM) and BaCl2 (1 μM) still significantly reduced the relaxation evoked by FLNT. Pretreatment of vessels with hydroxocobalamin, a nitric oxide scavenger, abolished the FLNT effect. These findings demonstrate that FLNT induces relaxation of the rat aorta rings en- dothelium-independently. Furthermore, we demonstrated that FLNT-induced vasorelaxation is related to its stimulation of soluble guanylate cyclase and activation of K+ channels. Keywords: organic nitrate, vasorelaxation, guanylate cyclase, K+ channel Introduction (ALDH-2), and possibly esterases in vitro and in vivo (5, 6). Nitric oxide (NO) is an important regulator of vascular A few evidences indicate that vascular smooth muscle smooth muscle. It stimulates soluble guanylyl cyclase is responsible for denitration and release of NO from (sGC), which catalyzes the conversion of guanosine nitrate which in turn activates sGC (7). However, evi- 5-trisphosphate (GTP) to cyclic guanosine monophos- dences have accumulated to support the endothelium- phate (cGMP), and cGMP may induce vasodilation dependent mechanism of nitrate-induced vasorelaxation through activation of myosin light chain phosphatase (1). (8, 9). Moreover, nitrate tolerance has been reported to NO also causes membrane hyperpolarization through be associated with effects of nitrate on the vascular + 2+ K -channel activation, decreasing Ca entry and leads to endothelium leading to NO synthase activation and L- vasodilatation (2, 3). NO is produced either through the arginine depletion (8, 9). In addition, the tolerance was endogenous L-arginine–citrulline–NO pathway or from a also associated with sGC desensitization to NO because pharmacological NO donor. The organic nitrates are the of increased reactive oxygen species production and S- most commonly used NO donors and mimic endogenous nitrosylation of sGC (10 – 12). However, slight or no NO (3, 4). They are suggested to bio-transform into NO tolerance was developed against a nitrate, like nicorandil, by enzymes such as glutathione S-transferase, cyto- with the property of opening K+ channels (13, 14). chrome P-450, mitochondrial aldehyde dehydrogenase Ferulate nitrate (FLNT), N-2-(ferulamidoethyl)-nitrate is a newly synthesized ferulate derivative. Ferulate is an *Corresponding author. [email protected] antioxidant and protects vascular endothelium cells from Published online in J-STAGE being injured by hyperlipidemic serum. We have previ- doi: 10.1254/jphs.11179FP ously demonstrated that FLNT was an orally efficacious 521 522 Z-Q Wang et al antianginal agent (15). FLNT possesses a nitrate moiety g, Certification No. SCHK-JING-2000-0010), purchased in its chemical structure (Fig. 1). So we hypothesize that from Experimental Animal Breeding Center of Chinese FLNT will also possess potential vasorelaxant activity. Medical Institute (Beijing, China), were sedated via an- The aim of the present study was to determine whether esthetic overdose and killed by cervical dislocation and FLNT induces vasorelaxation in rat aorta artery and to exsanguination. Thoracic aortas were dissected free and address whether sGC and different K+ channels are re- surrounding connective tissues were carefully removed. sponsible for the vasorelaxation induced by FLNT. Four aortic rings (2 mm in length) were prepared from each rat and bathed in 10-ml organ baths containing Materials and Methods Krebs solution of the following composition: 116.3 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 1.04 mM NaH2PO4, Chemicals 0.83 mM MgSO4, 19 mM NaHCO3, 5.5 mM glucose, pH FLNT (99.3% purity) was synthesized in our labo- 7.4. The bath solution was constantly gassed with a ratory; phenylephrine hydrochloride, acetylcholine mixture of 95% O2 and 5% CO2 and maintained at 37°C. chloride, 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one Before the experiments were carried out, the aortic rings (ODQ), nicorandil, 8-bromoguanosine 3,5-cyclic mono- were allowed to equilibrate under a resting tension of 1.5 phosphate (8-Br-cGMP), hydroxocobalamin hydrochlo- g for 1 h, during which time Krebs solution was replaced ride, glibenclamide (GLM), charybdotoxin (CHT), every 15 min and muscle tensions were readjusted to 1.5 4-aminopiridine (4-AP), and barium chloride (BaCl2) g. Contractions were recorded isometrically by means of were purchased from Superior Chemical & Instrument four-channel JZ101 force transducers (Xin-Hang Instru- Co. (Beijing, China). All drugs were dissolved in Krebs- ment, Gao-beidian, China) and stored on computer using Henseleit solution except for FLNT, ODQ, nicorandil, Medlab-U-4CS software (Mei-Yi Instrument, Nan-jing, and GLM, which were dissolved in dimethyl sulfoxide. China). The endothelium-denuded rings were made by Dimethyl sulfoxide at a final concentration of 0.2% (v/v) rubbing the lumen of the artery with a steel wire. The did not affect phenylephrine-induced contraction. All removal of the endothelium was deemed successful if no drugs were added directly to the bath in a volume of 10 relaxation was induced in response to acetylcholine (10 mL and the concentrations given are the calculated final μM), and if the relaxation response was more than 80%, concentrations in the bath solution. the ring was deemed endothelium-intact, as described previously (16). Preparation of aortic rings All experiments reported here abided by the Guide for Phenylephrine contractions and FLNT relaxation the Care and Use of Laboratory Animals published by In the first set of experiments, the aortic rings were the US National Institutes of Health (NIH publication contracted with cumulative concentration of phenyleph- NO. 85-23, revised 1996). The experiments were con- rine (0.001 – 100 μM). The contraction concentration– ducted with the approval of the Ethics Review Committee response curves of phenylephrine were then conducted. for Animal Experimentation of the General Hospital of Based on the integrated concentration–response curve, Being Military Command. Male Wistar rats (250 – 300 the 80% maximally effective concentration of phenyleph- rine (1 μM) was selected as the concentration used for pre-contraction of the vessel rings in all the subsequent experiments. Cumulative relaxation responses to FLNT were then studied in the endothelium-intact and -denuded rings, with a 2-min exposure to each FLNT concentra- tion. The relaxation induced by FLNT was also compared to those induced by typical vasodilators: isosorbide dini- trate, nicorandil, nitroglycerin, and 8-Br-cGMP in en- dothelium-intact rings. In the second group of experiments, endothelium-intact aorta arteries were pre-incubated for 5 min with FLNT (1, 10, and 100 μM). The effect of FLNT on the contrac- tion concentration–response curves of phenylephrine was studied. During the experiments, aortic rings were washed by changing the Krebs solution four times at 15-min intervals and then allowed to stabilize between Fig. 1. Chemical structure of FLNT. each FLNT concentration pre-incubation. Vasorelaxation Evoked by FLNT 523 + Studies with K -channel blockers and the drug concentration exhibiting 50% of the Emax As described previously (6, 17 – 20), experiments (EC50) were calculated from the fitted concentration– were performed with CHT (0.1 μM), a selective Ca2+- response curves for each ring. Data were expressed as the + activated K -channel (KCa) blocker, as well as the inward mean ± S.E.M.; n refers to the number of rats from which + rectifier K -channel (KIR) blocker BaCl2 (1 μM). Experi- the vessel ring segments were taken. When the data were ments were also performed with the ATP-sensitive K+- distributed normally, statistical analysis was performed channel (KATP) blocker GLM (1 μM) and voltage-depen- using repeated-measures of analysis of variance, fol- + dent K -channel (KV) blocker 4-AP (1 mM). Tissues lowed by Dunnett’s test to analyze the difference between were pre-incubated with the K+-channel blockers 45 min the control group and experiment groups. The difference before contractions with 1 μM phenylephrine, and then was considered
Recommended publications
  • Comparison of the Antiischaemic and Antianginal Effects of Nicorandil and Amlodipine in Patients with Symptomatic Stable Angina Pectoris: the SWAN Study
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 1999; 2 (2), 213-217 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL The SWAN study J Clin Basic Cardiol 1999; 2: 213 Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study The SWAN Study Group1 This multicentre, double-blind, randomised study compared the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris. Nicorandil is a new coronary and balanced peripheral vasodilating agent that operates through two mechanisms of action: activation of ATP-dependent K-channels and stimulation of guanylate cyclase. A total of 121 patients with symptomatic stable angina pectoris were randomised to receive nicorandil 10 mg twice daily (bd) or amlodipine 5 mg once daily (od) for 8 weeks (optional dosage increase after 2-4 weeks to 20 mg bd and 10 mg od, respec- tively). Symptom-limited exercise tolerance tests were performed at baseline, and after 2 and 8 weeks treatment, respectively. In addition, the number of anginal attacks, nitroglycerin (NTG) usage, blood pressure (BP), heart rate (HR) and adverse events were recorded, and a subjective assessment of quality of life performed.
    [Show full text]
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Current Status of Local Penile Therapy
    International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81 ß 2002 Nature Publishing Group All rights reserved 0955-9930/02 $25.00 www.nature.com/ijir Current status of local penile therapy F Montorsi1*, A Salonia1, M Zanoni1, P Pompa1, A Cestari1, G Guazzoni1, L Barbieri1 and P Rigatti1 1Department of Urology, University Vita e Salute – San Raffaele, Milan, Italy Guidelines for management of patients with erectile dysfunction indicate that intraurethral and intracavernosal injection therapies represent the second-line treatment available. Efficacy of intracavernosal injections seems superior to that of the intraurethral delivery of drugs, and this may explain the current larger diffusion of the former modality. Safety of these two therapeutic options is well established; however, the attrition rate with these approaches is significant and most patients eventually drop out of treatment. Newer agents with better efficacy-safety profiles and using user-friendly devices for drug administration may potentially increase the long-term satisfaction rate achieved with these therapies. Topical therapy has the potential to become a first- line treatment for erectile dysfunction because it acts locally and is easy to use. At this time, however, the crossing of the barrier caused by the penile skin and tunica albuginea has limited the efficacy of the drugs used. International Journal of Impotence Research (2002) 14, Suppl 1, S70–S81. DOI: 10.1038= sj=ijir=3900808 Keywords: erectile dysfunction; local penile therapy; topical therapy; alprostadil Introduction second patient category might be represented by those requesting a fast response, which cannot be obtained by sildenafil; however, sublingual apomor- Management of patients with erectile dysfunction phine is characterized by a fast onset of action and has been recently grouped into three different may represent an effective solution for these 1 levels.
    [Show full text]
  • Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART
    Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART Isosorbide Generic Nitroglycerin Nitroglycerin Nitroglycerin Nitroglycerin Dinitrate Isosorbide Isosorbide Name Intravenous Patch Ointment Sublingual Sublingual Dinitrate 5-Mononitrate Trade Name TRIDIL, NITRODUR, NITROL NITROLINGUAL generics generics (for IMDUR, generics TRANSDERM- Pumpspray, immediate generics NITRO, RHO-NITRO release) MINITRAN, Pumpspray, SR: no longer TRINIPATCH NITROLINGUAL available Metered dose spray NITROSTAT sublingual tablet Dosage 100 mg/250 mL 0.2 mg/h 30 g/30 inches SL spray: SL tablet: 5mg Immediate SR tablet: Forms premixed bottle 0.4 mg/h ointment 0.4 mg/ dose release 60 mg SR - UHN 0.6 mg/h SL tablet: tablet: Note: 0.84 mL 0.8 mg/h 0.3 mg, 0.6 mg 10 mg *Non- alcohol per 100 mL 30 mg formulary at solution UHN 100 mcg/mL 200 mcg/mL 400 mcg/mL 10 mg/10 mL vial - UHN 50 mg/10 mL vial - UHN CARDIOVASCULAR PHARMACOTHERAPY HANDBOOK All contents copyright © University Health Network. All rights reserved Cardiovascular Drugs and Therapies NITRATES COMPARISON CHART Isosorbide Generic Nitroglycerin Nitroglycerin Nitroglycerin Nitroglycerin Dinitrate Isosorbide Isosorbide Name Intravenous Patch Ointment Sublingual Sublingual Dinitrate 5-Mononitrate Dosing Starting and 0.2 to 0.8 ½ inch to 1 inch SL spray: SL tablet: Immediate 60-240 mg SR Usual dose target doses mg/h once tid-qid; remove 0.4 mg prn; 5-10 mg q2-4h release: once daily range are determined daily. for 8-10 hours dose may be for prophylaxis 10-45 mg tid by clinical per 24-hour repeated after of acute angina on qid situation and 12-14 hour period; 5 minutes for schedule the number and patch-free response to interval e.g., ON 0600, total of 3 doses (e.g.
    [Show full text]
  • Sgc Stimulators and Activators
    International Cardiovascular Forum Journal 18 (2019) 2 | Reviews DOI: 10.17987/icfj.v18i0.609 sGC Stimulators and Activators Heli Tolppanen1, Piotr Ponikowski2 1. Helsinki University Central Hospital, Helsinki, Finland 2. Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland Corresponding author: Prof. Piotr Ponikowski, Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland. Email: [email protected] Abstract Nitric oxide (NO)-soluble guanylate cyclase(sGC)-cGMP signalling is impaired in HF syndromes, which could predispose to vascular oxidative stress. Nitrates directly stimulate cGMP, but are limited by tolerance. Therapeutic targets that aim at increasing cGMP concentrations have therefore been explored. Recently, two classes of drugs have been discovered, the sGC activators and the sGC stimulators, which target two different redox states of sGC: the NO-sensitive reduced (ferrous) sGC and NO-insensitive oxidized (ferric) sGC, respectively. Cinaciguat is an activator and riociguat and vericiguat are sGC stimulators. Vericiguat is the most advanced agent in its clinical trial programme with two completed phase IIb studies, SOCRATES -REDUCED in HFrEF and SOCRATES-PRESERVED in HFpEF, with mixed results on NT-proBNP. The ongoing VICTORIA trial in HFrEF will study 4,872 participants with a mortality/morbidity end-point and VITALITY HFpEF trial will study 735 participants, with a quality of life end- point. Keywords: heart failure; sGC activators; sGC stimulators; vericiguat Citation: Tolppanen H, Ponikowski P.
    [Show full text]
  • Irreversible Activation and Stabilization of Soluble Guanylate Cyclase by The
    Molecular Pharmacology Fast Forward. Published on November 14, 2017 as DOI: 10.1124/mol.117.109918 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109918 Irreversible activation and stabilization of soluble guanylate cyclase by the protoporphyrin IX mimetic cinaciguat Alexander Kollau, Marissa Opelt, Gerald Wölkart, Antonius C.F. Gorren, Michael Russwurm, Doris Koesling, Bernd Mayer and Astrid Schrammel Downloaded from Department of Pharmacology and Toxicology, University of Graz, Austria molpharm.aspetjournals.org (A.K., M.O., G.W., A.C.F.G., B.M., A.S.) Department of Pharmacology and Toxicology, Ruhr University Bochum, Bochum, Germany (M.R., D.K.) at ASPET Journals on September 29, 2021 1 Molecular Pharmacology Fast Forward. Published on November 14, 2017 as DOI: 10.1124/mol.117.109918 This article has not been copyedited and formatted. The final version may differ from this version. MOL #109918 Running Title: Irreversible activation of sGC by cinaciguat Address correspondence to: Dr. Astrid Schrammel Department of Pharmacology and Toxicology Karl-Franzens-Universität Graz Humboldtstrasse 46, A-8010 Graz, Austria Downloaded from Tel.: +43-316-380-5559 Fax: +43-316-380-9890 e-mail: [email protected] molpharm.aspetjournals.org Number of text pages: 24 Number of tables: – at ASPET Journals on September 29, 2021 Number of figures: 3 Number of references: 27 Number of words in Abstract: 236 Introduction: 436 Discussion: 904 1Abbreviations: DEA/NO, 2,2-diethyl-1-nitroso-oxyhydrazine; DTT, dithiothreitol; IBMX, 3-isobutyl-1-methylxanthin; NO, nitric oxide; ODQ, 1H-[1,2,4]oxadiazolo-[4,3- a]quinoxalin-1-one; PDE, phosphodiesterase; sGC, soluble guanylate cyclase; 2 Molecular Pharmacology Fast Forward.
    [Show full text]
  • The Availability of Organic Nitrates from Intravenous Administration Systems
    THE AVAILABILITY OF ORGANIC NITRATES FROM INTRAVENOUS ADMINISTRATION SYSTEMS by Paul Adrian Cossum B.Sc., M.P.S. submitted in partial fulfilment of the requirements for the degree of Master of Pharmacy UNIVERSITY OF TASMANIA - HOBART JUNE 1981 SUMMARY Nitroglycerin aind isosorbide dinitrate are two drugs which are infused intravenously during the treatment of ischaemic heart disease. The availability of these two drugs in solutions infused from plastic infusion bags or glass infusion bottles through plastic giving sets has been investigated. During simulated infusions the concentration of nitroglycerin and isosorbide dinitrate appearing in the effluent of the • giving set tubing was found to be much less than the concentration of the drug solution initially contained in the plastic infusion bag or glass infusion bottle. It was found that each component of the plastic infusion equipment sorbed the drugs to a significant extent and that the rate of disappearance of drugs from solutions stored in each component was in the rank order: giving set tubing > giving set burette > plastic infusion bag. There was no significant loss of either drug from solutions stored in glass bottles. The influence of formulation factors and storage conditions on the sorption of nitroglycerin, isosorbide dinitrate and another organic nitrate compound., ethylene glycol dinitrate, by plastic infusion equipment was studied. The extent of loss during simulated infusions was also found to be dependent on flow rate of drug solution through the giving set. The sorption of nitroglycerin and isosorbide dinitrate has clinical and pharmacokinetic significance. Losses of nitroglycerin and isosorbide dinitrate associated with their infusion through plastic Lnfusion equipment were minimised by infusing drug solutions from a glass syringe through high density polyethylene tubing.
    [Show full text]
  • Use of Sildenafil in Patients with Cardiovascular Disease
    Arq Bras Cardiol GuimarãesReview et al volume 73, (nº6), 1999 Sildenafil in patients with cardiovascular disease Use of Sildenafil in Patients with Cardiovascular Disease Armênio Costa Guimarães, Marcus Vinícius Bolívar Malachias, Otávio Rizzi Coelho, Emílio Cesar Zilli, Rafael Leite Luna Introduction of phosphodiesterase inhibitors. The erectile action of sildenafil combines increase in arterial flow with reduction Erectile dysfunction, formerly called impotence, is the in the venous flow of cavernous body of penis. Sildenafil inability of the male to achieve or maintain penile erection and leads to relaxation of smooth muscle of penile arteries and thus engage in coitus1. It is common among patients with trabeculae surrounding the sinusoidal spaces, resulting in cardiovascular diseases or their risk factors. This dysfunc- a greater engorgement of cavernous body. The trabeculae tion occurs mainly among individuals with coronary artery of engorged sinusoidal spaces compress the penile disease, after episodes of acute ischemic syndrome, hyper- venules against the tunica albuginea, reducing venous tensive patients underpharmacologic treatment, and among flow, contributing to maintenance of engorgement of patients with heart failure. In approximately 85% of these ca- cavernous body8. Relaxation of this smooth muscle ses, the fear of a cardiac event during coitus constitutes an results from a decrease in intracellular calcium mediated important factor for erectile dysfunction 2-4. by accumulation of the second messenger, the cyclic Discovery of sildenafil citrate has represented a great de- guanosine monophosphate (cGMP), whose production velopment in the treatment of erectile dysfunction; it may results from activation of guanyl cyclase by nitric oxide benefit, among many others, those patients with cardiovascu- produced by the stimulus of endothelial cells generated lar diseases or with their risk factors 5.
    [Show full text]
  • REVATIO (Sildenafil Citrate) – Product Monograph Page 52 of 55 PART
    IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION o nitroglycerin (sprays, ointments, skin patches or pastes, and tablets that are swallowed or dissolved in PrREVATIO® the mouth) (sildenafil tablets, Upjohn Standard) o isosorbide mononitrate and isosorbide dinitrate 20 mg sildenafil as (sildenafil citrate) (tablets that are swallowed, chewed, or dissolved in the mouth) (sildenafil injection, Upjohn Standard) If you are not sure if any of your medicines contain nitrates, 0.8 mg/mL sildenafil as (sildenafil citrate) or if you do not understand what nitrates are, ask your doctor or pharmacist. If you take REVATIO with any nitrate- READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR containing medicine or any nitrate, your blood pressure could MEDICINE. suddenly drop to a life-threatening level. You could get Read this carefully before you start taking REVATIO and each dizzy, faint, or even have a heart attack or stroke. time you get a refill. This leaflet is a summary and will not tell have loss of vision in one or both eyes from an eye disease you everything about this drug. Talk to your healthcare called non-arteritic anterior ischaemic optic neuropathy professional about your medical condition and treatment and ask (NAION) if there is any new information about REVATIO. ® take drugs like ketoconazole (Nizoral ), itraconazole (Sporanox®), ritonavir (Kaletra®) ABOUT THIS MEDICATION have pulmonary hypertension secondary to sickle cell anaemia (abnormality of the red blood cells) What the medication is used for: have severe liver disease REVATIO (sildenafil citrate) is used to treat pulmonary arterial have a recent history of stroke or heart attack or life- hypertension (high blood pressure in the blood vessels between the threatening arrhythmia (a heart rhythm disorder) heart and the lungs) in adults (18 years of age or older).
    [Show full text]
  • WORKING PROGRAM Pharmacology
    Северный государственный медицинский университет г. Архангельск «СОГЛАСОВАНО» «УТВЕРЖДАЮ» Зав. кафедрой фармакологии, Декан международного д.м.н. И.А. Крылов факультета врача общей практики, д.м.н. В.А. Болдуев «______»_____________ 20 11 г. «______»_____________ 20 11 г. WORKING PROGRAM Pharmacology (for general practitioners) The international faculty (course “English Medium”) Chair of Pharmacy and Pharmacology Years ________III_________________________________________________ The terms _____5, 6_______________________________________________ Lectures _____52_____ (hours) End-of-year examination - __sixth___ term Practical classes _____110___ (hours) The test ______5_______ (term) Total hours ______162_____ Arkhangelsk, 20 11 г. 2 The working program is arranged in accordance with: 1. State educational standard for general practitioner. 2. Pharmacology programs (2002). 3. The curriculum the North State Medical University. Working program was confirmed on the chair conference « » ___________ 200_11_ Head of chair Ilya. A. Krylov 3 Part I THE OBJECT AND THE TASKS OF DISCIPLINE, ITS PLACE IN CURRICULUM 1.1. The purpose of analysis of pharmacology is the acquisition by each stu- dent of a profound knowledge on pharmacology, to orient of the effects of drugs on the function of living systems; skills to use the obtained know- ledge at the subsequent analysis of other fundamental and clinical discip- lines, and also future practical activity of the doctor. 1.2. The students it is ground analyses of practical and idealized sections of pharmacology: Should know: 1) Milestones of a history of pharmacology. 2) Methods of pharmacological researches and pharmacological terms (de- finitions). 3) Pharmaceutical classes of the drugs (pharmacologic classification). 4) Chemistry characteristics of main groups of the drugs. 5) Mechanism of action of the drugs (pharmacological actions).
    [Show full text]
  • The Nitric Oxide Donor, Isosorbide Dinitrate, Induces a Cephalic
    The nitric oxide donor, isosorbide dinitrate, induces a cephalic cutaneous hypersensitivity, associated with sensitization of the medullary dorsal horn Running Title: nitric oxide donors induced central sensitization José Maria Ramos Flores, Laurent Devoize, Amélie Descheemaeker, Jean-Louis Molat, Philippe Luccarini, Radhouane Dallel To cite this version: José Maria Ramos Flores, Laurent Devoize, Amélie Descheemaeker, Jean-Louis Molat, Philippe Luc- carini, et al.. The nitric oxide donor, isosorbide dinitrate, induces a cephalic cutaneous hypersensi- tivity, associated with sensitization of the medullary dorsal horn Running Title: nitric oxide donors induced central sensitization: Nitric oxide donors induced central sensitization. Neuroscience, Else- vier - International Brain Research Organization, 2017, 10.1016/j.neuroscience.2016.12.028. inserm- 01458345 HAL Id: inserm-01458345 https://www.hal.inserm.fr/inserm-01458345 Submitted on 6 Feb 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. The nitric oxide donor, isosorbide dinitrate, induces a cephalic cutaneous hypersensitivity, associated with sensitization of the medullary dorsal horn José María Flores Ramos1, Laurent Devoize1,2, Amélie Descheemaeker1, Jean-Louis Molat1, Philippe Luccarini1, Radhouane Dallel1,2 1Clermont Université, Université d’Auvergne, Neuro-Dol, BP 10448, F-63000, Clermont- Ferrand & Inserm U1107, F-63100 Clermont-Ferrand, France; 2CHU Clermont-Ferrand, Service d’Odontologie, F-63100 Clermont-Ferrand, France.
    [Show full text]
  • Fast Dissolving Sublingual Strips: a Novel Approach for the Delivery Of
    Pharmaceutical Sciences December 2019, 25(4), 311-318 doi: 10.15171/PS.2019.34 https://ps.tbzmed.ac.ir/ Research Article Fast Dissolving Sublingual Strips: A Novel Approach for the Delivery of Isosorbide Dinitrate Marziyeh Fathi1 , Mitra Alami-Milani2,3, Sara Salatin1,3, Sharahm Sattari4, Hassan Montazam5, Farhad Fekrat3, Mitra Jelvehgari2,6* 1Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran. 2Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 3Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. 4Nikookari Ophtalmology Center, Tabriz University of Medical Sciences, Tabriz, Iran. 5Islamic Azad University of Bonab Unit, Bonab, Iran. 6Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. A r t i c l e I n f o A B S T R A C T Article History: Background: Isosorbide dinitrate (ISDN) is used for treating the angina attacks. In Received: 19 November 2018 addition, oral ISDN is available in immediate and sustained release formulations and the Revised: 6 April 2019 Accepted: 12 April 2019 bioavailability of ISDN is about 20-25% when taken orally. Further, the ISDN films are ePublished: 20 December 2019 developed for sublingual drug delivery by improving drug bioavailability. The present study aimed to design and evaluate the physicochemical properties of the film formulation Keywords: for sublingual delivery of ISDN. -Film -Sublingual Methods: In the present study, sublingual films were prepared by the solvent casting -Isosorbide dinitrate technique using the hydroxypropyl methylcellulose (HPMC) polymers (i.e., 100, 150 and -HPMC 200 mg) with a different drug to polymer ratios (i.e., 1:5, 1:7.5 and 1:10).
    [Show full text]